GlaxoSmithKline

3,628 clinical trials · Sponsor

Record	Firm	Date
Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults (NCT00696891)	GlaxoSmithKline	1997-06-01
Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders (NCT00697931)	GlaxoSmithKline	1997-05-01
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs). (NCT00697216)	GlaxoSmithKline	1997-03-01
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y (NCT00698555)	GlaxoSmithKline	1997-03-01
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma (NCT00989664)	GlaxoSmithKline	1996-11-01
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects (NCT00698568)	GlaxoSmithKline	1996-10-01
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma (NCT00996996)	GlaxoSmithKline	1996-06-01
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease (NCT00699764)	GlaxoSmithKline	1996-03-01
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma (NCT00002767)	GlaxoSmithKline	1996-01-01
Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (NCT01224821)	GlaxoSmithKline	1995-12-01
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines (NCT00698490)	GlaxoSmithKline	1995-08-01
Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B (NCT00697840)	GlaxoSmithKline	1995-06-01
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B (NCT00698087)	GlaxoSmithKline	1995-01-01
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults (NCT00697242)	GlaxoSmithKline	1994-01-01
Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine (NCT00697970)	GlaxoSmithKline	1993-11-01
Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants (NCT00697125)	GlaxoSmithKline	1993-06-01
Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules (NCT00697229)	GlaxoSmithKline	1992-09-01
Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant (NCT00697567)	GlaxoSmithKline	1992-09-01
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults (NCT00698893)	GlaxoSmithKline	1992-05-01
Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients (NCT00699231)	GlaxoSmithKline	1992-02-01
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma (NCT01536561)	GlaxoSmithKline	1990-04-24
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma (NCT02416232)	GlaxoSmithKline
Managed Access Program for Momelotinib in Myelofibrosis (NCT05582083)	GlaxoSmithKline
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic (NCT00244686)	GlaxoSmithKline
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma (NCT03702036)	GlaxoSmithKline
Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma (NCT03763370)	GlaxoSmithKline
Compassionate Use for Subcutaneous (SC) Belimumab (NCT03125486)	GlaxoSmithKline
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC) (NCT05448170)	GlaxoSmithKline

Track GlaxoSmithKline automatically

Every clearance here is in the API, with alerts when new ones post.